CA2636909A1 - Inhibition of inflammatory cytokine production with tanshinones - Google Patents

Inhibition of inflammatory cytokine production with tanshinones Download PDF

Info

Publication number
CA2636909A1
CA2636909A1 CA002636909A CA2636909A CA2636909A1 CA 2636909 A1 CA2636909 A1 CA 2636909A1 CA 002636909 A CA002636909 A CA 002636909A CA 2636909 A CA2636909 A CA 2636909A CA 2636909 A1 CA2636909 A1 CA 2636909A1
Authority
CA
Canada
Prior art keywords
tanshinone
disease
mammal
sepsis
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002636909A
Other languages
English (en)
French (fr)
Inventor
Haichao Wang
Dazhi Chen
Andrew E. Sama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2636909A1 publication Critical patent/CA2636909A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
CA002636909A 2006-01-13 2007-01-12 Inhibition of inflammatory cytokine production with tanshinones Abandoned CA2636909A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75923706P 2006-01-13 2006-01-13
US60/759,237 2006-01-13
PCT/US2007/000945 WO2007084419A2 (en) 2006-01-13 2007-01-12 Inhibition of inflammatory cytokine production with tanshinones

Publications (1)

Publication Number Publication Date
CA2636909A1 true CA2636909A1 (en) 2007-07-26

Family

ID=38288155

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002636909A Abandoned CA2636909A1 (en) 2006-01-13 2007-01-12 Inhibition of inflammatory cytokine production with tanshinones

Country Status (7)

Country Link
US (1) US8513227B2 (https=)
EP (1) EP1981489B1 (https=)
JP (1) JP5247469B2 (https=)
CN (1) CN101394860B (https=)
AU (1) AU2007207675B2 (https=)
CA (1) CA2636909A1 (https=)
WO (1) WO2007084419A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101327249B (zh) * 2007-06-21 2012-07-18 天津天士力制药股份有限公司 二羟基苯基乳酸在制备治疗败血症的药物中的应用
WO2010088786A1 (zh) * 2009-02-06 2010-08-12 Lin Xiuying 具有cox-2和免疫活性的草药组合物及其制备方法
MX339842B (es) * 2009-12-22 2016-06-14 Avon Prod Inc Composiciones estimuladoras de paxilina y usos cosmeticos de las mismas.
US20110159125A1 (en) 2009-12-29 2011-06-30 Avon Products, Inc. CGRP Compositions and Uses Thereof
ES2413437T3 (es) * 2010-03-10 2013-07-16 Institut Pasteur HMGB1 y anticuerpos anti-HMGB1 en pacientes infectados por VIH especialmente con trastornos neurológicos
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) * 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
CN102949399B (zh) * 2011-08-23 2016-02-24 上海中医药大学附属岳阳中西医结合医院 丹参酮iia在制备抑制角质形成细胞增殖疾病药中的应用
KR101612051B1 (ko) * 2011-12-20 2016-04-27 한국생명공학연구원 단삼 추출물을 포함하는 코로나 바이러스 감염의 예방 또는 치료용 조성물
KR101400900B1 (ko) * 2012-01-26 2014-05-29 한국생명공학연구원 탄시논을 유효성분으로 함유하는 자연살해세포 분화 또는 활성 증진용 조성물
CN102670768A (zh) * 2012-05-15 2012-09-19 宋协勘 一种治疗急性阑尾炎的中药
CN102824349A (zh) * 2012-09-14 2012-12-19 广东省中医院 丹参酮ⅱa在制备治疗银屑病药物中的应用
CN102973575A (zh) * 2012-11-23 2013-03-20 广东省中医院 隐丹参酮在制备治疗银屑病药物中的应用
CN103006549B (zh) * 2012-12-05 2015-04-15 广东宏远集团药业有限公司 采用助溶消泡溶剂制备丹参酮iia磺酸钠制剂的方法
CN103040837A (zh) * 2013-01-13 2013-04-17 广东宏盈科技有限公司 一种眼科外用降眼压药物
GB201312205D0 (en) * 2013-07-08 2013-08-21 Univ Leuven Kath Anticonvulsant activity of dan shen extracting compounds
KR20170006030A (ko) * 2015-07-07 2017-01-17 재단법인 진안홍삼연구소 크립토탄시논을 유효성분으로 포함하는 구강세균 독성에 의한 염증을 예방, 개선 또는 치료하는 조성물
CN105168222A (zh) * 2015-07-23 2015-12-23 南京赋海澳赛医药科技有限公司 组合物及其在抗鼻炎药物中的应用
US11266716B2 (en) 2015-10-22 2022-03-08 The Feinstein Institutes For Medical Research Use of dermcidin in sterile inflammatory conditions
CN108264515B (zh) * 2017-01-04 2021-01-12 中国科学院上海药物研究所 一类苯并[def]咔唑类化合物及其制备方法和应用
CN106924740A (zh) * 2017-03-15 2017-07-07 河南科技大学 一种治疗急性肺损伤的药物组合物
CN106963776A (zh) * 2017-04-26 2017-07-21 上海市疾病预防控制中心 一种化合物在制备以组织蛋白酶k为靶标的疾病药中的应用
CN108785314A (zh) * 2017-05-03 2018-11-13 阎永平 用于治疗和预防酒精性肝病的药物及其组合物
US11026905B2 (en) 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
JP7411315B2 (ja) 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
CN108685981A (zh) * 2018-07-20 2018-10-23 深圳市博奥生物科技有限公司 一种三七丹参胶囊及其制备方法
CN108837001A (zh) * 2018-07-20 2018-11-20 深圳市博奥生物科技有限公司 一种三七丹参片及其制备方法
AU2019374135A1 (en) * 2018-11-02 2021-06-17 University Of Maryland, Baltimore Inhibitors of Type 3 Secretion System and antibiotic therapy
JP2023520273A (ja) 2020-01-24 2023-05-17 トゥヴァルディ セラピューティクス，インク． 治療化合物、製剤、およびその使用
CN111166754A (zh) * 2020-02-25 2020-05-19 上海市第六人民医院 隐丹参酮在制备防治恶病质骨骼肌萎缩药物中的应用
CN111214467A (zh) * 2020-03-05 2020-06-02 南京巴傲得生物科技有限公司 吲哚布洛芬在抵抗hmgb1促炎活性中的应用
CN113679726B (zh) * 2020-05-18 2025-01-10 上海科技大学 丹参提取物和醌类化合物在抗冠状病毒中的应用
CN111528098A (zh) * 2020-06-10 2020-08-14 甘肃省农业科学院经济作物与啤酒原料研究所（甘肃省农业科学院中药材研究所） 一种当归组培苗生根培养方法
CN115025103A (zh) * 2021-03-04 2022-09-09 上海上药第一生化药业有限公司 丹参酮iia磺酸钠在制备药物中的应用
CN113005130B (zh) * 2021-03-18 2022-07-08 上海辰山植物园 丹参酮ⅱa合酶基因及应用
CA3254067A1 (en) 2022-06-15 2023-12-21 Tvardi Therapeutics, Inc. STAT3 INHIBITOR MEDICINES
CN119950521A (zh) * 2025-01-14 2025-05-09 浙江工业大学 丹参酮i在制备治疗艾滋病的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0830077B2 (ja) * 1987-04-24 1996-03-27 晟 八木 虚血性疾患治療剤
CN1304723A (zh) 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
CN1251718C (zh) * 2003-05-13 2006-04-19 天津红日药业股份有限公司 一种预防、治疗脓毒症的中药复方制剂及其制备方法
JP2007517025A (ja) * 2003-12-30 2007-06-28 エムディー バイオアルファ カンパニー リミテッド 代謝活性を上昇させるタンシノン誘導体を用いる、肥満およびメタボリックシンドロームの治療
KR100725839B1 (ko) * 2005-10-06 2007-12-11 일성신약주식회사 단삼으로부터 분리된 탄시논류의 화합물을 함유하는인지기능 장애의 예방 및 치료용 조성물

Also Published As

Publication number Publication date
AU2007207675B2 (en) 2013-01-31
AU2007207675A1 (en) 2007-07-26
EP1981489A2 (en) 2008-10-22
US20090221542A1 (en) 2009-09-03
EP1981489B1 (en) 2013-05-01
EP1981489A4 (en) 2010-07-28
JP2009523730A (ja) 2009-06-25
CN101394860A (zh) 2009-03-25
WO2007084419A3 (en) 2008-10-09
WO2007084419A2 (en) 2007-07-26
US8513227B2 (en) 2013-08-20
CN101394860B (zh) 2013-05-29
JP5247469B2 (ja) 2013-07-24

Similar Documents

Publication Publication Date Title
US8513227B2 (en) Inhibition of inflammatory cytokine production with tanshinones
US12083114B2 (en) Inhibitors of SARM1 in combination with neuro-protective agents
US20260034156A1 (en) Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
Li et al. A Cardiovascular Drug Rescues Mice from Lethal Sepsis by Selectively Attenuating a Late-Acting Proinflammatory Mediator, High Mobility Group Box
Sarmah et al. Sirtuin-1-mediated NF-κB pathway modulation to mitigate inflammasome signaling and cellular apoptosis is one of the neuroprotective effects of intra-arterial mesenchymal stem cell therapy following ischemic stroke
CA2566445C (en) Methods related to the treatment of neurodegenerative and inflammatory conditions
US9662347B2 (en) Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
Kikuchi et al. The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells
Wu et al. Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity
US20100292157A1 (en) Combination Treatments for Alzheimer's Disease and Similar Diseases
KR20090026247A (ko) 단백질 응집 장애의 치료를 위한 사이클로헥산 폴리알콜 제형
JP2019507796A (ja) イカリイン及びイカリチン誘導体
EP3831821A1 (en) Compound for treating nervous system diseases and use thereof
US11376233B2 (en) Composition, containing sarpogrelate as active ingredient, for preventing or treating sensorineural hearing loss
EP4138840A1 (en) Compositions and methods for treating metabolic and cardiovascular diseases
EP3071234A1 (en) Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy
KR102600785B1 (ko) 페놀산 유도체를 유효성분으로 포함하는 식욕 억제용 조성물
JP2011037722A (ja) 小胞体ストレスによる神経細胞死の予防又は抑制剤
US20210087214A1 (en) Therapeutic drug for neurodegenerative disease and application thereof
CA3135943A1 (en) Novel compound and method for preventing or treating of respiratory disease comprising the same as an active ingredient
CN109939116A (zh) Rock2抑制剂在制备药物中的用途
Malik Doxorubicin-induced cardiomyopathy: role of endoplasmic reticulum stress
JP2009126801A (ja) セスキテルペンラクトンを含有する抗酸化ストレス剤
Yeboah Characterizing the Role of Histone Deacetylase 2 (HDAC2) in Mitochondria Function and Alzheimer’s Disease
CN115515580A (zh) 使用碳硼烷和碳硼烷类似物调节t细胞活化的方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150113